132 related articles for article (PubMed ID: 38910605)
1. Adrenal Insufficiency and Thyrotoxicosis Following Combined Immune Checkpoint Inhibitor Use: A Case Report and Literature Review.
Fukushima K; Kitayama S; Sazuka M; Kodera R; Oba K; Toyoshima K; Chiba Y; Yamamoto H; Araki A; Tamura Y
Cureus; 2024 May; 16(5):e60850. PubMed ID: 38910605
[TBL] [Abstract][Full Text] [Related]
2. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
[TBL] [Abstract][Full Text] [Related]
3. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
[TBL] [Abstract][Full Text] [Related]
4. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
Ariyasu H; Inaba H; Ota T; Yamaoka H; Furukawa Y; Iwakura H; Doi N; Yamamoto Y; Akamizu T
In Vivo; 2018; 32(2):345-351. PubMed ID: 29475919
[TBL] [Abstract][Full Text] [Related]
5. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
6. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
7. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
8. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
[TBL] [Abstract][Full Text] [Related]
11. [An unusual association of transient resolving thyrotoxicosis due to painless thyroiditis, hypopituitarism and central diabetes insipidus associated with spontaneous pituitary apoplexy].
Sasaki H; Ohnishi O; Maehara F; Akiyoshi K; Kan K; Katakabe K; Yamamoto T; Okumura M
Nihon Naibunpi Gakkai Zasshi; 1990 Jan; 66(1):9-21. PubMed ID: 2307257
[TBL] [Abstract][Full Text] [Related]
12. Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient.
Spagnolo CC; Campo I; Campennì A; Cardile D; Cannavò S; Silvestris N; Santarpia M; Ruggeri RM
Hormones (Athens); 2024 Feb; ():. PubMed ID: 38421588
[TBL] [Abstract][Full Text] [Related]
13. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis.
Bando H; Yamamoto M; Urai S; Motomura Y; Sasaki Y; Ohmachi Y; Kobatake M; Tsujimoto Y; Oi-Yo Y; Suzuki M; Yamamoto N; Takahashi M; Fukuoka H; Iguchi G; Ogawa W
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38418395
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Manaka K; Sato J; Takeuchi M; Watanabe K; Kage H; Kawai T; Sato Y; Miyagawa T; Yamada D; Kume H; Sato S; Nagase T; Iiri T; Nangaku M; Makita N
Sci Rep; 2021 Jun; 11(1):11617. PubMed ID: 34078988
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.
Daetwyler E; Zippelius A; Danioth S; Donath MY; Gut L
Front Immunol; 2023; 14():1248919. PubMed ID: 37965350
[TBL] [Abstract][Full Text] [Related]
16. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab Induced Adrenal Insufficiency: Rare Side-effect of a New Anti-cancer Therapy - Immune-checkpoint Inhibitors.
Rai M; Go M
Cureus; 2020 Apr; 12(4):e7625. PubMed ID: 32399358
[TBL] [Abstract][Full Text] [Related]
18. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
19. An unusual case of hypopituitarism and transient thyrotoxicosis following asymptomatic pituitary apoplexy.
Yoshida M; Murakami M; Ueda H; Miyata M; Takahashi N; Oiso Y
Neuro Endocrinol Lett; 2014; 35(5):342-6. PubMed ID: 25275254
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-induced hypophysitis with transient ACTH-dependent hypercortisolism.
AlRubaish FA; Gupta N; Shi MZ; Christopoulos S
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]